Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7569578 | 0.85 | DRD4 (0.56) | DRD4DRD2DRD3HTR2AHTR2C | |
| SCHEMBL12675300 | 0.81 | DRD4 (0.52) | DRD4DRD2DRD3HTR2AHTR2C | |
| SCHEMBL1647156 | 0.78 | DRD4 (0.50) | DRD4DRD2DRD3HTR2AHTR2C | |
| SCHEMBL4392263 | 0.77 | DRD4 (0.70) | DRD4DRD2DRD3HTR2AHTR2C | |
| SCHEMBL2597773 | 0.76 | DRD4 (0.72) | DRD4DRD2DRD3HTR2AHTR2C | |
| SCHEMBL2876563 | 0.75 | DRD4 (1.00) | DRD4DRD2DRD3HTR2AHTR2C | |
| SCHEMBL3134694 | 0.75 | ALDH1A1 (0.63) | DRD4DRD2DRD3ALDH1A1TSHR | |
| SCHEMBL6773141 | 0.75 | MAPT (0.52) | DRD4DRD2DRD3HTR2AHTR2C | |
| SCHEMBL418557 | 0.75 | DRD4 (0.57) | DRD4DRD2DRD3SIGMAR1HTR7 | |
| SCHEMBL13902706 | 0.75 | DRD2 (1.00) | DRD4DRD2DRD3HTR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-01-03 | — | — | US | disclosed |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | DR. REDDY'S LABORATORIES LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| US-20150126525-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | REDDYS LAB LTD DR (IN) | 2015-05-07 | — | — | US | disclosed |
| EP-1233961-B9 | METHOD FOR PRODUCING 5-(1-PIPERAZINYL)-BENZOFURAN-2-CARBOXAMIDE BY TRANSITION METAL-CATALYZED AMINATION | MERCK PATENT GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-1233961-B9 | METHOD FOR PRODUCING 5-(1-PIPERAZINYL)-BENZOFURAN-2-CARBOXAMIDE BY TRANSITION METAL-CATALYZED AMINATION | MERCK PATENT GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-1233961-B1 | METHOD FOR PRODUCING 5-(1-PIPERAZINYL)-BENZOFURAN-2-CARBOXAMIDE BY TRANSITION METAL-CATALYZED AMINATION | MERCK PATENT GMBH (DE) | 2005-07-06 | — | — | EP | disclosed |
| US-6762300-B2 | ONE POT; SUCH AS CYCLIZATION OF 5-BROMOSALICYLALDEHYDE WITH ETHYL BROMOACETATE AND REACTING WITH FORMAMIDE THEN WITH PIPERAZINE DERIVATIVE | MERCK PATENT GMBH (DE) | 2004-07-13 | — | — | US | disclosed |
| US-20030125558-A1 | Method for producing 5-(1-piperazinyl) -benzofuran-2-carboxamide by transition metal-catalyzed amination | MERCK PATENT GMBH (DE) | 2003-07-03 | — | — | US | disclosed |
| EP-1233961-A2 | METHOD FOR PRODUCING 5-(1-PIPERAZINYL)-BENZOFURAN-2-CARBOXAMIDE BY TRANSITION METAL-CATALYZED AMINATION | MERCK PATENT GmbH (DE) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040219-A2 | METHOD FOR PRODUCING 5-(1-PIPERAZINYL)-BENZOFURAN-2-CARBOXAMIDE BY TRANSITION METAL-CATALYZED AMINATION | MERCK PATENT GMBH (DE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126525-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | DRD4 258/4885DRD2 1013/4885DRD3 826/4885 |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | DRD4 391/4885DRD2 1290/4885DRD3 955/4885 |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | VIL1, VMA21, PYGL | DRD4 391/4885DRD2 1290/4885DRD3 955/4885 |
| US-20030125558-A1 | Method for producing 5-(1-piperazinyl) -benzofuran-2-carboxamide by transition metal-catalyzed amination | PARP15, TPMT, TPH2 | DRD4 1169/4885DRD2 740/4885DRD3 1238/4885 |
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | DRD4 391/4885DRD2 1290/4885DRD3 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.